Biocatalysis is a useful tool in the provision of chiral technology and extremophilic enzymes are just one component in that toolbox. Their role is not always attributable to their extremophilic properties; as with any biocatalyst certain other criteria should be satisfied. Those requirements for a useful biocatalyst will be discussed including issues of selectivity, volume efficiency, security of supply, technology integration, intellectual property and regulatory compliance. Here we discuss the discovery and commercialization of an l-aminoacylase from Thermococcus litoralis, the product of a LINK project between Chirotech Technology and the University of Exeter. The enzyme was cloned into Escherichia coli to aid production via established mesophilic fermentation protocols. A simple downstream process was then developed to assist in the production of the enzyme as a genetically modified-organism-free reagent. The fermentation and downstream processes are operated at the 500 litre scale. Characterization of the enzyme demonstrated a substrate preference for N-benzoyl groups over N-acetyl groups. The operational parameters have been defined in part by substrate-concentration tolerances and also thermostabilty. Several examples of commercial biotransformations will be discussed including a process that is successful by virtue of the enzyme's thermotolerance.
Introduction
Biocatalysis is well established as a key technology in the provision of chiral intermediates and active pharmaceutical ingredients. Extremophilic organisms are often proposed as sources of industrially relevant enzymes, not only because of their innate properties but also the diversity of the Kingdom Archaea to which many belong [1] . However, the ability to withstand the rigorous environments that industrial processes present is not sufficient alone for commercial exploitation, and a number of other factors must also be considered.
Ideally, the enzyme would complement an existing technology portfolio or provide a technology capability that offers a competitive advantage. A suitable intellectual property position must also be available. Freedom to operate is essential and thus a careful evaluation of the external intellectual property landscape is needed. In addition, an organization may consider patent protection for a new biocatalyst as a means to establish competitive advantage.
An enzyme must possess high selectivity, preferably being entirely stereospecific. It should also have broad substrate specificity. Potential biocatalysts should also be active at industrially relevant volume efficiencies. In a simple batch reactor, this would typically mean at a minimum of 50 g/l substrate. The substrate/catalyst ratio must also be satisfactory. During the early stage of a project, when only a few kilograms of product are required, 1 g of wild-type cells/g of product may be tolerable. However, as a product matures this may be difficult to scale up, both from process considerations of product isolation and economics of biomass production. In our experience this requires cloning of the enzyme and development of a fermentation capable of matching the growing product volume needs. Regulatory issues prevent the use of live genetically modified organisms at non-licensed premises [2] . For this reason the development of a simple downstream process to prepare a cell-free enzyme reagent is useful, especially if a third party is required to perform the chemistry at scale. Again, this issue has multiple facets and the extra time and complexity of producing such a reagent is often offset by simplifying the process chemistry, after the biotransformation, by avoiding emulsions brought about by cell debris during organic extractions. This paper will discuss the development and successful commercialization of a thermophilic L-aminoacylase from the archaeon Thermococcus litoralis and give consideration to the factors that have made it successful in our business.
Discovery and development of an l-aminoacylase
The discovery of the L-aminoacylase from T. litoralis was somewhat fortuitous. A LINK program between Chirotech Technology and the University of Exeter had found a pyrrolidone carboxylpeptidase through the screening of a genomic library of T. litoralis [3] . Sequencing of the 4.6 kb fragment demonstrated several open reading frames. Similarity searches of the nucleotide sequence demonstrated that the upstream open reading frame was putatively a novel carboxypeptidase. This was subcloned, via the introduction of 
Enzyme characterization
The T. litoralis L-aminoacylase was shown to be a 172 kDa homotetrameric protein made up of 43 kDa monomers. It is a metalloprotein binding Zn 2+ , although this is thought to be structural rather than catalytic, as activity is not completely inhibited by the addition of EDTA [4] .
The L-aminoacylase of T. litoralis has broad substrate specificity for the hydrolysis of N-acylated α-amino acids, with respect to both the side chain and the N-acyl group. The ability to remove different acyl groups, particularly aromatic groups, is a distinguishing feature from the commercially available L-aminoacylase of Amano. Besides the ability to hydrolyse a variety of acyl groups, the enzyme was completely enantiospecific for L-amino acids. A 100-fold preference for N-benzoyl-L-tryptophan over Nacetyl-L-tryptophan was demonstrated, with lower but significant rates of hydrolysis for benzyloxycarbonyl and t-butoxycarbonyl protecting groups. The enzyme hydrolysed a broad selection of amino acid side chains, both natural and unnatural, showing the following preference:
The enzyme activity was shown to be maximal at 85
• C but with a half life limited to 1.7 h. Reduction of the operating temperature to 70
• C yields a significant increase in t 1/2 to 25 h. The pH optimum was shown to be pH 8 but more than 70% of the maximal activity remained over the range pH 6.5-9.5. The standard assay for the enzyme was then defined using 50 mM N-benzoyl-L-phenylalanine, run for 30 min at 80
• C in Tris/HCl, pH 8.0, with 1 unit of activity being expressed as the amount of enzyme capable of producing 1 µmol of product/min. Above 50 mM it was also noted that, under these conditions, substrate inhibition was observed.
Fermentation and downstream processing
A key aspect in any biotransformation process is to ensure security of supply of the enzyme. This can be achieved by developing sufficient capability to produce the enzyme to your required specification. The recombinant L-aminoacylase has been grown at 500 litre scale using a generic fed-batch fermentation. This had previously been used successfully for other recombinant biocatalyst production via the E. coli DH5/pUCcer host/vector combination, thereby reducing development time and costs. The pUCcer11 vector is not well repressed and, as such, the complex amino acid and glycerol carbon-sourced media permitted leaky expression throughout the 40 h fermentation cycle. Cells were harvested by centrifugation and the resultant cell mass stored at −20
• C, with no loss of activity over several months.
As the enzyme was to be used at a third-party manufacturing site or by our own synthetic chemists it was essential that the enzyme be prepared as a cell-free extract. This avoids the need for microbiological disposal procedures, so as to prevent the accidental release of genetically modified organisms, which is subject to regulatory requirement. To this end we developed a simple downstream process, involving the minimum of steps to provide the enzyme as a reagent solution. Only a 2-fold purification was achieved, in reality little more than removal of the cell mass. However, purity of catalyst is of little consequence for several reasons. In a recombinant system it is not necessary to purify away competing activities that might otherwise compromise the selectivity or specificity of the reaction. In addition, extensive purification is costly and adds little value, when the catalyst is to be used in a disposable fashion.
Briefly, the process outheading is as follows; cells are mechanically disrupted using a bead mill. The resultant lysate is then subject to a flocculation step and subsequent centrifugation. The centrifuged lysate is then treated with (NH 4 ) 2 SO 4 . The precipitate is then removed by passage through a coarsegrade Cuno brand lenticular filter. The filtrate is taken to higher saturation and L-aminoacylase containing precipitate is then allowed to form. This is captured on a second finer filter. The protein precipitate is then resuspended by the recirculation of fresh buffer and allowed to pass through the filter [5] . This achieves both concentration and clarification in one step. A typical recovery from one 500 litre fermentation (around 30-40 kg of cells) is approx. 70% or 80 million units.
Commercial applications
Value is derived not only from the ability of the T. litoralis L-aminoacylase to accept a wide range of amino acid side chains and N-protecting groups. It complements both our Dacylase and our chemocatalytic asymmetric hydrogenation capabilities, providing a general method for α-amino acid synthesis, and in turn supports our catalogue business selling N-protected amino acids.
Several example biotransformations are discussed below. The first shows how cell-free extracts offer advantage over powdered enzymes. The resolution of N-acyl-proparglycine operates at 70
• C and a concentration of 80 g/l, requiring some 260 units of enzyme/g of substrate. A N-t-butoxycarbonyl protection is performed in the same pot at room temperature prior to extraction with methyl tert-butyl ether. Provision of the reagent solution of L-aminoacylase results in significant process improvement since it permits a simple filtration of the organic aqueous mixture through a glass-fibre filter membrane. The equivalent process run using the commercially available Amano L-aminoacylase requires two slow filtrations, through a celite bed, to remove the emulsified enzyme. The second example shows the advantages of integrated technology providing access to compounds that are otherwise difficult to produce. The production of N-acetyl neopentylglycine is not easy by the well-known Erlenmeyer chemistry [6] . However, novel chemistry is able to deliver the enamide of N-benzoyl neopentylglycine. Asymmetric hydrogenation using a (S,S)-Et-DuPHOS-Rh catalyst [7] reduces this with high enantiomeric excess (>97%ee) to the N-benzoyl-L-neopentylglycine, which is not a substrate for the Amano L-aminoacylase (Scheme 2). However, the broader substrate specificity of T. litoralis L-aminoacylase permits the deprotection, and increases the enantiomeric excess to >99%. This reaction requires 500 units of enzyme/g of substrate and is complete overnight at 70
• C and 50 g/l substrate. In contrast the chemical deprotection would involve boiling in 20 equivalents of 6 M HCl for 2 days.
Finally, our most developed application of the T. litoralis L-aminoacylase demonstrates a unique advantage that only a thermophilic enzyme can provide. This process, for a customer product, is the resolution of an N-acyl-protected amino acid and has already been used to supply >100 kg of product. The solubility of the protected amino acid at ambient temperature is poor. This can be addressed by warming the racemic N-acylamino acid to above 50 • C. At such temperatures the Amano acylase is inactive, but this suits the T. litoralis L-aminoacylase. The reaction utilizes 240 units of enzyme/g of substrate at 230 g/l and conversion is complete in 8-10 h at 70
• C. The largest batch size to date is 190 kg of racemate producing 65 kg of amino acid, requiring 45 million units, about half of one 500 litre fermentation.
Conclusion
The choice of whether to develop an enzyme into a commercial entity is not wholly reliant on the enzyme's innate properties. Extremophilic enzymes are no exception. Freedom to operate and the appropriate development capability are required to mature an enzyme discovery into a commercially viable technology. The development process discussed shows how the L-aminoacylase of T. litoralis was discovered and how it has been developed so as to become useful to our business. Several examples are shown of biotransformations that make use of this L-aminoacylase but which do not take advantage of its thermophilic properties. However, to date the largest-scale application of this enzyme has arisen because of its thermophilic properties; enabling the deprotection of an otherwise insoluble N-acylamino acid to provide large quantities of amino acid.
